startup

Lindis Biotech

Development of Triomab® antibodies - a new class of T-cell activating bispecific antibodies that enable the immune system to transform malignant cancers into treatable and potentially curable diseases.
  • Life Science & Healthcare
  • Steady Stage
  • Other
  • B2B
  • 2010
  • 1-10 Employees
  • Found
  • Planegg, DE
  • Login required
  • Lindis Biotech GmbH
  • Bayern

Profile is not claimed et

This profile is created by the Startbase Analyst Team. If you are a team member of this company you can claim the profile in order to make changes to it.

Is this your company? Claim profile
Horst Lindhofer Geschäftsführer

News about Lindis Biotech

FYI: English edition available

Hello my friend, have you been stranded on the German edition of Startbase? At least your browser tells us, that you do not speak German - so maybe you would like to switch to the English edition instead?

Go to English edition

FYI: Deutsche Edition verfügbar

Hallo mein Freund, du befindest dich auf der Englischen Edition der Startbase und laut deinem Browser sprichst du eigentlich auch Deutsch. Magst du die Sprache wechseln?

Deutsche Edition öffnen